Here, the D-MS assay profoundly improves treatment decision making by identifying up to 5.5fold more high-risk CLL than the gold standard analysis for del(17p)/TP53 mutation with a specificity of 75%–92%. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.